Skip to main content

Abstract

Early post-transplant factors including delayed graft function (DGF), acute rejection episodes, nephrotoxic agents, post-transplant hypertension, dyslipidemia, and new onset diabetes mellitus after transplantation (NODAT) have all been implicated in worsening both short- and long-term morbidity and mortality after renal transplantation. Optimal management of the transplant recipient begins in the immediate postoperative period. This chapter provides a stepwise approach to the medical and urological management of the transplant recipient in the first 3 months after transplantation. The management of transplant recipients can be divided into three periods: immediate postoperative period, first week post-transplant, and first 3 months post-transplant. Immunosuppressive therapy is discussed in Chapter 9.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shokes DA, Cecka JM. Effect of delayed graft function on short- and long-term kidney graft survival. In: Cecka JM and Terasaki PI (eds.), Clinical Transplants. UCLA Tissue typing Laboratory, Los Angeles, CA, 1997, pp. 297–303.

    Google Scholar 

  2. Lehtonen SRK, Isoniemi HM, Salmela KT et al. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 1997;64:103–107.

    Article  CAS  PubMed  Google Scholar 

  3. Paff WW, Howard RJ, Patton HP et al. Delayed graft function after renal transplantation. Transplantation 1998;65:219–223.

    Google Scholar 

  4. Ojo AO, Wolfe RA, Held WP et al. Delayed graft function: risk factors and implication for renal allograft survival. Transplantation 1997;63:968–974.

    Article  CAS  PubMed  Google Scholar 

  5. Marcen R, Orofino L, Pascual J et al. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 1998;66:461–466.

    Article  CAS  PubMed  Google Scholar 

  6. Dawidson I et al. Perioperative albumin and verapamil improve early outcome after cadaveric renal transplantation. Transplant Proc 1994;26:3100–3101.

    CAS  PubMed  Google Scholar 

  7. Gritsch HA, Rosenthal JM. The transplant operation and its surgical complications. In: GM Danovitch, (ed.), Handbook of Kidney Transplantation, 3rd ed. Lippincott, Williams and Wilkins, Philadelphia, PA, 2001, pp. 146–162.

    Google Scholar 

  8. Gritsch HA, Rosenthal JT, Danovitch GM. Living and cadaveric kidney donation. In Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown, Boston, 2001, pp. 111–129.

    Google Scholar 

  9. Fotiadas CN, Govani MV, Heldeman JH. Renal allograft dysfunction. In Massary SG, Galssock RJ (eds.), Textbook of Nephrology. Lippincott, Williams and Wilkins, Philadelphia, 2001, pp. 1617–1635.

    Google Scholar 

  10. Pham PT, Pham PC, Wilkinson AH. Management of the transplant recipient in the early postoperative period. In: Davison AM, Cameron JS, Grunfeld J-P, Ponticelli C, Ritz E, Winearls C, van Ypersele C (eds), Oxford Textbook Of Clinical Nephrology, 3rd ed. Oxford University Press, Oxford/New York, 2005, pp. 2087–2101.

    Google Scholar 

  11. Fernandez-Najera JE, Beltran S, Aparicio M et al. Transplant renal artery stenosis: association with vascular rejection. Transplant Proc 2006;38(8):2404–2405.

    Article  CAS  PubMed  Google Scholar 

  12. Hawkins IF, Maynar M. Carbon dioxide digital subtraction angiography. In: Castadena Z (ed), Interventional Radiology, 3rd ed. Williams and Wilkins, Philadelphia, PA, 1997.

    Google Scholar 

  13. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008;67(Suppl 3):66–69.

    Article  Google Scholar 

  14. Ploeg RJ, van Bockel JH, Langendijk PT et al. for the European Multicentre Study Group: Effect of preservation solution on results of cadaveric kidney transplantation. Lancet 1992;340:129–137.

    Article  CAS  PubMed  Google Scholar 

  15. Yarlagadda SG, Klein CL, Jani A. Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis 2008;15(3):248–256.

    Article  PubMed  Google Scholar 

  16. Shokes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management, and long-term significance. J Urol 1996;155:1831-1840.

    Article  Google Scholar 

  17. Phillips AO, Deanne C, O’Donnell P et al. Evaluation of Doppler ultrasound in primary non-function of renal transplants. Clin Transplant 1994;8:83–86.

    CAS  PubMed  Google Scholar 

  18. Pham PT, Peng A, Wilkinson AH et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000;36:844–850.

    Article  CAS  PubMed  Google Scholar 

  19. Barone GW, Gurley BJ, Abul-Ezz SR et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003;42:202–206.

    Article  PubMed  Google Scholar 

  20. Baid S, Pascual M, Williams WW et al. Renal thrombotic microangiopathy associated with anti-cardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999;10:146–153.

    CAS  PubMed  Google Scholar 

  21. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006;6:2535–2542.

    Article  CAS  PubMed  Google Scholar 

  22. Sharma M, Sharma R, Reddy SR et al. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002;73(3):366–372.

    Article  PubMed  Google Scholar 

  23. Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13:2420–2423.

    Article  PubMed  Google Scholar 

  24. Mauiyyedi S, Covin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002;11:609–618.

    Article  PubMed  Google Scholar 

  25. Solez K, Colvin RB, Racusen LC et al. Banff 2007 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8(4): 753–760.

    Google Scholar 

  26. Gaber AO et al. Results of double blind, randomized, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute allograft rejection episodes after renal transplantation. Transplantation 1998;96:29–37.

    Article  Google Scholar 

  27. Ibernon M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005;37(9):743–745.

    Article  Google Scholar 

  28. 28. Jordan SC, Vo AA, Tyan D et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005;9(3):408–415.

    Google Scholar 

  29. Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003;76(10):1444–1447.

    Article  CAS  PubMed  Google Scholar 

  30. Berger PM, Diamond JR. Ureteral obstruction as complication of renal transplantation: a review. J Nephrol 1998;11:20–23.

    CAS  PubMed  Google Scholar 

  31. Nargund VH, Cranston D. Urologic complications after renal transplantation. Transplant Rev 1996;10:24.

    Article  Google Scholar 

  32. Mylonakis E, Goes N, Rubin RH et al. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation 2002;72:1587–1592.

    Article  Google Scholar 

  33. Singer J, Gritsch AH, Rosenthal JT. The transplant operation and its surgical complications. In: Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown, Boston, 2004, pp. 193–211.

    Google Scholar 

  34. Jaster R, Bittorf T, Klinken SP et al. Inhibition of proliferation but not erythroid differentiation of j2E cells by rapamycin. Biochem Pharmacol 1996;51:1181–1185.

    Article  CAS  PubMed  Google Scholar 

  35. Augustine JJ, Rodriguez V, Padiyar A et al. Reduction of erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation 2008;86(4):548–553.

    Article  CAS  PubMed  Google Scholar 

  36. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036–1042.

    Article  CAS  PubMed  Google Scholar 

  37. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-1260.

    Article  CAS  PubMed  Google Scholar 

  38. Luisa M et al. Thrombotic microangiopathy associated with parvovirus B19 infection after renal transplantation. J Am Soc Nephrol 2000;11:1132-1137.

    Google Scholar 

  39. Hartmann EL, Gatesman M, Roskopf-Somerville J et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008;22(6):822–888.

    Article  PubMed  Google Scholar 

  40. 40. Vlahakos DV, Marathias KP, Agroyannis B et al. Posttransplant erythrocytosis. Kidney Int 2003;63(4):1187–1194.

    Google Scholar 

  41. Bacon BR, Rothman SA, Ricanati ES et al. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980;140:1206–.

    Article  CAS  PubMed  Google Scholar 

  42. Wicker CG, Norman DJ, Bennison A et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983;23:731–.

    Article  Google Scholar 

  43. Brox AG et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding protein. Transplantation 1998;66:1053–1058.

    Article  CAS  PubMed  Google Scholar 

  44. Gupta M, Miller BA, Ahsan N et al. Expression of angiotensin II type 1 receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplantation 2000;70(8):1188–1194.

    Article  CAS  PubMed  Google Scholar 

  45. Lezaic V et al. Erythrocytosis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells. Eur Med Res 2001;6:27–32.

    CAS  Google Scholar 

  46. Heering P, Degenhart S, Garbensee B. Tubular dysfunction following kidney transplantation. Nephron 1996;74:501–511.

    Article  CAS  PubMed  Google Scholar 

  47. 47. Pirenne J, Lledo-Garcia E, Benedetti E et al. Colon perforation after renal transplantation a single-institution review. Clin Transplant 1997; 11(2): 88–93.

    Google Scholar 

  48. 48. Ward HN, Pabico RC, McKenna BA et al. The renal handling of phosphate by renal transplant recipients: correlation with serum parathyroid hormone, cyclic 3′5′-adenosine monophosphate urinary excretion and allograft function. Adv Exp Med Biol 1997;81:173–181.

    Google Scholar 

  49. Kawarazaki H, Shibagaki Y, Shimizu H et al. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol 2007;11(3):255–257.

    Article  PubMed  Google Scholar 

  50. Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006;15(2):97–104.

    Article  CAS  PubMed  Google Scholar 

  51. Levi M. Post transplant hypophosphatemia. Kidney Int 2001; 59:2377–2387.

    Google Scholar 

  52. Serra AL, Wuhmann C, Wuthrich RP. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008;52(6):1151–1157.

    Article  CAS  PubMed  Google Scholar 

  53. Borchhardt KA, Heinz H, Mayerwoger E et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008;86(7):919–924.

    Article  CAS  PubMed  Google Scholar 

  54. Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1311–1314.

    Article  CAS  PubMed  Google Scholar 

  55. Bergua C, Torregrosa JV, Fuster D et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86(3):413–417.

    Article  CAS  PubMed  Google Scholar 

  56. Pham PC, Pham PT:. Parathyroidectomy. In: Nissebson AR and Fine RN, (eds.), Handbook of Dialysis Therapy. Saunders, Elsevier, London, 2008, pp. 1024–1038.

    Chapter  Google Scholar 

  57. Barton CH. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987;83:693–699.

    Article  CAS  PubMed  Google Scholar 

  58. Gupta BK, Glicklich TVA. Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients. Transplantation 1999;67:1485-1487.

    Article  CAS  PubMed  Google Scholar 

  59. Gane E, Pilmore H. Management of chronic hepatitis before and after renal transplantation. Transplantation 2002;74:427–437.

    Article  CAS  PubMed  Google Scholar 

  60. Fabrizio F, Martin P. In: Danovitch GM(ed.). Handbook of Kidney Transplantation. Hepatitis in kidney Transplantation, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, PA, 2001, pp. 263–271.

    Google Scholar 

  61. Fasola CG, Netto G, Christensen LL et al. Delay of hepatitis recurrence in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002;34:1561–1562.

    Article  CAS  PubMed  Google Scholar 

  62. Bahra M, Neumann UIF, Jacob D et al. MMF and calcineurin inhibitor taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005;5:406–411.

    Article  CAS  PubMed  Google Scholar 

  63. Nanmoku K, Imaizumi R, Tojimbra T et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. Transplant Proc 2008;40(7):2382–2385.

    Article  CAS  PubMed  Google Scholar 

  64. Amend WJ, Vincenti I, Tamlonovich SJ. The first two post-transplant months. In: Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown & Co, Boston, 2001, p. 167.

    Google Scholar 

  65. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4(7): 1033–1041.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Phuong-Thu T. Pham MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag US

About this chapter

Cite this chapter

Pham, PT.T., Pham, PC.T., Danovitch, G.M. (2010). The Acute Care of the Transplant Recipient. In: McKay, D., Steinberg, S. (eds) Kidney Transplantation: A Guide to the Care of Kidney Transplant Recipients. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1690-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1690-7_14

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1689-1

  • Online ISBN: 978-1-4419-1690-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics